Apollo Cancer Centres (ACC) has achieved a milestone by completing its CAR-T cell programme, marking the introduction of indigenous CAR-T cell therapy in India. Led by T. Raja, Director of Medical Oncology at ACC, the program focuses on providing ‘Made in India’ CAR-T cell therapy, starting with Actalycabtagene autoleucel.
This therapy targets B-cell lymphomas and B-acute lymphoblastic leukemia in patients aged 15 and above. CAR-T cell therapy involves genetically modifying a patient’s T-cells to express chimeric antigen receptors (CARs) designed to recognize cancer cells. Dr. Raja reported successful treatment of six patients using CAR-T cell therapy, marking a significant advancement in combating these malignancies.
With the transition to indigenously developed therapy, ACC aims to provide cutting-edge solutions for cancer patients, as emphasized by Preetha Reddy, Executive Vice-Chairperson of Apollo Hospitals Enterprise Limited. The initiative represents a new era in innovative cancer treatments, ensuring advanced care for those battling B-cell lymphomas and acute lymphoblastic leukemia.